Chronic Kidney Disease: When 35.5 Million Patients Become an Evidence Strategy Challenge
- 2 minutes ago
- 1 min read
We have more chronic kidney disease (CKD) therapies than ever before.
So why are so many patients with chronic kidney disease still being diagnosed late, progressing faster than expected, or falling through gaps in care?
That is the uncomfortable reality facing CKD today.
More than 35 million Americans are living with chronic kidney disease, yet most remain unaware they even have it. And for many patients, kidney disease does not happen in isolation. It overlaps with type 2 diabetes, hypertension, cardiovascular disease, poverty, environmental exposure, geography, and unequal access to specialty care.
The problem is no longer innovation alone but whether our healthcare evidence systems, clinical trial models, and real-world evidence strategies actually reflect the patients carrying the greatest burden of disease.
In this new white paper, we explore why CKD has become one of the clearest examples of a population-level evidence challenge and why healthcare leaders, pharmaceutical companies, clinical research teams, and medical affairs stakeholders need equity-stratified real-world evidence to support better clinical outcomes, treatment access, long-term safety monitoring, and clinical trial decision-making.
Because if the data does not reflect real-world CKD patients, healthcare decisions eventually break down too.
Download the white paper below to explore the future of chronic kidney disease evidence generation, clinical trials, healthcare equity, and real-world patient outcomes.